 pilot study intermediate-dose methotrexate cytosine arabinoside spread-out up-front continuation therapy childhood non-T non-B acute lymphoblastic leukemia Pediatric Oncology Group study children non-T- non-B-cell acute lymphoblastic leukemia Pediatric Oncology Group POG pilot study courses intermediate-dose methotrexate MTX cytosine arabinoside Ara-C backbone standard continuation therapy dose sequence MTX/Ara-C administration preclinical model synergism MTX Poor-risk patients up-front therapy MTX/Ara-C courses initial weeks remission Standard-risk patients spread-out therapy MTX/Ara-C courses intervals continuation treatment Toxicity intermediate-dose MTX/Ara-C neutropenia fever significant manageable incidence fever neutropenia spread-out therapy up-front therapy years Kaplan-Meier estimate event-free survival EFS standard-risk patients poor-risk patients results pilot study use intermediate-dose MTX/Ara-C additional studies